Product analysis
Niacin 500 mg has a possible connection to blood-fat changes, but its exact niacin form is unclear. That matters because different niacin forms do not share the same effects.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality0
The broad vitamin B3 description does not establish the exact niacin form. That limits confidence in applying benefits associated with a specific preparation.
Ingredient Transparency100
The serving amount is clear and a vitamin B3 form description is provided. The description is still too broad to distinguish between different niacin preparations.
Value For Money40
Value is limited by uncertainty about the exact niacin preparation. A serving-cost comparison alone cannot show that it provides the effects expected from a particular form.
Customer Satisfaction87
Customer ratings are favorable across a large review pool. They do not establish effects on blood fats or cardiovascular outcomes.
Product Focus68
The formula focuses on niacin, with a possible connection to blood-fat measurements. Changes in those measurements do not establish fewer cardiovascular events, and the unclear form limits expectations.
- Format
Tablet - Container
- 250 Tablet(s)
- Per serving
- $0.06
- Customer rating
- 4.6 · 6,961 ratings
Goals
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Niacin (Vitamin B3) | 500 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability36
Niacin Form & Goal Alignment
Precursor Source Quality
Dose, Safety & Label Transparency37
Clarity of Chemical Form
Form-Specific Dosage Efficacy
Flush Risk & Safety Labeling
Value40
Price Per Effective Serving
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
- Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
- Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
- Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
- Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
- Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.